Oral Cyclic Melphalan and Dexamethasone for Patients With AL Amyloidosis
- 1 December 2010
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 10 (6), 469-472
- https://doi.org/10.3816/clml.2010.n.081
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Predictors of survival in patients with systemic light‐chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasoneBritish Journal of Haematology, 2008
- Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantationBlood, 2007
- Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete responseHaematologica, 2007
- High-Dose Melphalan versus Melphalan plus Dexamethasone for AL AmyloidosisThe New England Journal of Medicine, 2007
- An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosisAmyloid, 2007
- Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantationBlood, 2004
- High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year StudyAnnals of Internal Medicine, 2004
- Molecular Mechanisms of AmyloidosisThe New England Journal of Medicine, 2003
- A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and ColchicineThe New England Journal of Medicine, 1997
- Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine onlyThe American Journal of Medicine, 1996